Our Products

Product details Products Home
Metacard MR

Metacard MR

Trimetazidine Hydrochloride

Trimetazidine Hydrochloride is the new twice-daily formulation of the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients.
Trimetazidine inhibits fatty acid pathway by inhibiting 3-ketoacylCoA thiolase enzyme and transfers oxygen to glucose pathway.Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.

Product Details

Presentation

Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

Pharmacology

Trimetazidine Hydrochloride is the new twice-daily formulation of the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients.
Trimetazidine inhibits fatty acid pathway by inhibiting 3-ketoacylCoA thiolase enzyme and transfers oxygen to glucose pathway.Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.

Indication

Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.

Dosage & Administration

One tablet at mealtimes in the morning and evening.

Contraindications

Trimetazidine is contraindicated in-patients with a known hypersensitivity to its components.

Side effects

Trimetazidine is safe and well tolerated. Rare cases of gastrointestinal disorders, nausea & vomiting have been reported.

Drug interaction

No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidaemic agents or digitalis preparation.

Use in special groups

Use in Pregnancy: Studies in animals have not demonstrated teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.

Packing

Metacard MR Tablet: Each box contains 60's tablets in blister pack.

Other Products from
Cardiovascular
 
Digoxin
Bisoprolol Hemifumarate
Bisoprolol Fumarate + Hydrochlorothiazide
Valsartan
Aspirin + Clopidogrel
Metoprolol
Spironolactone + Furosemide
Candesartan
Candesartan + Hydrochlorothiazide
Enoxaparin Sodium
Isosorbide -5-Mononitrate
Lacidipine
Amlodipine + Atenolol
Amlodipine
Trimetazidine
Nitroglycerin
Diluted Nitroglycerin
Losartan
Losartan + Hydrochlorothiazide
Ramipril
Atenolol
Indapamide

© 2014. Aristopharma Ltd. All rights reserved.
Site by DIGITA iNTERACTIVE

HOME | PRODUCTS | FACILITIES | GLOBAL PRESENCE | NEWS | ABOUT US | CONTACT | CAREER

Bookmark and Share